March 28, 2024
Otsuka Pharmaceutical and Lundbeck said on March 27 that European regulatory authorities have approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia. The European Commission granted the green light on...read more